Our pipeline is guided by our commitment to provide patients around the world with access to best-in-class living drugs, with faster treatment timelines, wide range of cancers and other life threatening diseases

Product

Preclinical

Ph1

Ph2

Ph3

Native iNKT Cells
AGENT-797
Mechanism/Indication:
Solid Tumors
Anticipated Milestones:
H1-22: Phase 1 read-out
AGENT-797 + Checkpoint Antibodies
Mechanism/Indication:
Solid Tumors
including but not limited to NSCLC, HCC, SCCHN
Anticipated Milestones:
H1-22: Phase 1 read-out
AGENT-797
Mechanism/Indication:
r/r Multiple Myeloma
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Indication:
GvHD
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Indication:
ARDS Secondary to COVID-19
Anticipated Milestones:
IND Filing H1 ‘21
Engineered iNKT Cells
Mechanism/Indication:
BCMA-CAR-iNKT
Mechanism/Indication:
Stromal target-CAR-iNKT
Mechanism/Indication Product Preclinical Ph1 Ph2 Ph3 Anticipated Milestones
Native iNKT Cells
Solid TumorsAGENT-797H1-22: Phase 1 read-out
Solid Tumors
including but not limited to NSCLC, HCC, SCCHN		AGENT-797 + Checkpoint AntibodiesH1-22: Phase 1 read-out
r/r Multiple MyelomaAGENT-797Phase 1 Readout in Q4 ‘21
GvHDAGENT-797Phase 1 Readout in Q4 ‘21
ARDS Secondary to COVID-19AGENT-797IND Filing H1 ‘21
Engineered iNKT Cells
BCMA-CAR-iNKT
Stromal target-CAR-iNKT